Many tragic complications of diabetes, including amputations, heart attack, stroke, and blindness, are due to blood vessel damage. According to Xiaochao Wei, PhD, of the Washington University School of Medicine in St. Louis, all that vascular damage may be caused by a shortage of one enzyme: fatty acid synthase, or FAS.
Epic Wound Care, a subsidiary of New York-based United EcoEnergy Corp., has signed a three-year sponsorship agreement with the American Diabetes Association in support of the ADA's "Mission to Stop Diabetes®" campaign.
Data from the massive ACCORD study on intensive blood sugar control shows that lowering blood sugar levels in people with longstanding type 2 diabetes to near-normal may delay the appearance of signs that point to damage to nerves, eyes, and kidneys, but does not stop their progression toward it.
AARP today launched its second annual "Fat-to-Fit Summer Weight Loss Challenge," an online program challenging people to make positive, permanent lifestyle changes to improve their health. AARP's Fat-to-Fit challenge will be hosted on AARP's website (www.aarp.org/fat2fit). Fitness expert and author Carole Carson, a Nevada City, California, resident who lost more than 60 pounds at age 60, will lead Fat-to-Fit online community members through the summer-long program.
Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working age.¹ In the study, 37 percent of patients treated with MACUGEN gained two lines, or 10 letters, of vision on the ETDRS eye chart at 54 weeks, compared to 20 percent of patients who received a sham (placebo-like) procedure which consists of anesthesia and a simulated injection in the eye (p=0.0047). The data were presented at the World Ophthalmology Congress in Berlin by Frank G. Holz, an investigator in the trial and director of the University Eye Hospital at the University of Bonn in Germany.
Early management of type 2 diabetes with an integrated team of specialists, including a dietitian, diabetes educator, endocrinologist, cardiologist, and nephrologist, can significantly reduce the incidence of complications and lower healthcare costs, according to an online survey of more than 300 endocrinologists and family practice physicians. The survey was supported by Boehringer Ingelheim Pharmaceuticals, Inc., with the goal of determining the most common obstacles for physicians in treating type 2 diabetes patients and preventing complications. Sermo, the largest physician only online community, conducted the survey. A significant number of these physicians (44 percent) reveal that 50 percent of their patients develop at least one of the following serious complications: cardiovascular disease, nerve pain, kidney disease, stroke, blindness, or limb amputation.
Most women with gestational diabetes know that taking steps to manage the disease during pregnancy is critical for the health of both mother and child. What many women don't realize is that those steps need to continue even after the baby is born.
Clinical studies at 52 different sites nationwide have shown that combining standard laser treatments with injections of the drug ranibizumab (Lucentis) offers substantially better results for treating macular edema than laser treatments alone. The research showed that almost 50 percent of patients treated with the combination therapy showed substantial improvement in their vision after one year, compared with 28 percent of patients who had been treated solely with laser.
Researchers at Loyola University have discovered a group of immune system cells called natural killer T (NKT) cells that slow the wound healing process. Their findings pave the way for potential new treatments to accelerate the healing process in slow-to-heal wounds that can occur in people with autoimmune disorders such as type 1 diabetes.
Four risk factors-all of them preventable-reduce life expectancy among U.S. men by 4.9 years and among U.S. women by 4.1 years, according to a study by the Harvard School of Public Health and the Institute for Health Metrics and Evaluation at the University of Washington. (According to U.N. figures, current U.S. life expectancy is 75.6 years for men and 80.8 years for women.)
Successful clinical trials of a topical drug called mecamylamine may lead to a potent new treatment for the diabetes-induced eye disease known as macular edema. Diabetic macular edema* involves the part of the retina called the macula. High blood sugar levels inflame its blood vessels, leading to leakiness and fluid accumulation. Left uncontrolled, those symptoms can lead to blurriness, impaired vision, and even blindness.
"I think I'm the only blind principal in Los Angeles," stated Connie Gibson after she developed diabetic retinopathy, which later led to sudden vision loss after complications from laser surgery. Now age 59, Gibson is currently legally blind, but has been able to move forward with her life. She continues working and living an active lifestyle despite her disability.
Are you a scientific anomaly like me? Have you or someone you know reversed the complications associated with diabetes? Did you suffer microvascular and macrovascular damage during the “growing pains” of coming to terms with having no choice but to live your life with diabetes? Then, did you turn around and find love and hope, which made you change your life? And after changing it, did you find after several years that you were healing the damage that you had incurred by your own misguided hand?
The day I heard "Diabetes is not the leading cause of heart attack, blindness, kidney disease, and amputation," my life changed. I had believed the opposite to be true for the 32 years I'd been dealing with diabetes. Complications had always hung like a knife over my head.
The newly opened Center for Wound Care and Hyperbaric Medicine in Stoughton, Mass., is now offering comprehensive wound management care, including hyperbaric oxygen therapy (HBOT), which has been used successfully to treat diabetic ulcers.
July 27, 2008 marked the eighth full month that my son has not used insulin. His last A1c was 5.9%, on July 9, 2008. On August 14th of this year, it will be one year since he was originally diagnosed with type 1. As you know, he was taken off insulin on November 27, 2007, about a month after getting the experimental drug teplizumab. I don't know if it is the drug or not, but others have taken it with good results. It will be interesting to see if they ever get the drug approved and can use it quickly on newly diagnosed type 1s.
Scientists at Massachusetts General Hospital (MGH) in Boston have initiated a phase 1 clinical trial to reverse type 1 diabetes. The trial is exploring whether the promising results from the laboratory of Denise Faustman, MD, PhD, can be applied in human diabetes.
Let’s start from the beginning. First, you’ve got the endothelium. What’s that, you ask? Well, endo means “internal” and thelium means “cellular layer.” The endothelium, therefore, is the layer of cells that lines the heart, blood vessels, and certain other cavities in the body.
Nearly one-quarter of research subjects with type 1 diabetes who had diabetic kidney disease showed signs of remission of their kidney disorder after beginning treatment with angiotensin-converter enzyme (ACE) inhibitors, say researchers at the Steno Diabetes Center in Gentofte, Denmark.
Although the idea of preventing the onset of diabetes in people at risk for type 1 was recently introduced in the Diabetes Prevention Trial of Type 1 (DPT-1), a group of Italian researchers report that the treatment does not have similar effects in people who have already contracted the disease. In a study published in the August issue of Diabetologia, the researchers report that giving oral insulin to newly diagnosed individuals with diabetes may be doing too little too late.
In the March issue of the journal Nature Medicine, Ammon Peck, MD, and colleagues at the University of Florida in Gainseville, reported that the use of stem cells reversed diabetes in an animal model. Their experiment was the first to demonstrate that the cells were as valuable as researchers have speculated in treating diabetes.
The largest and longest study ever conducted to learn about the effects of a medication on people with nephropathy recently concluded. It found that a drug called Captopril can slow or halt the progression of nephropathy (kidney disease) in people with diabetes who show signs of this complication. Captopril is an ACE inhibitor, a medication used to treat hypertension.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health.
Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.